Aspirin Resistance in Coronary Artery Disease

• Status: Completed
• Trial end date: 2014-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate possible mechanisms of aspirin resistance at a molecular level in aspirin-treated patients with coronary artery disease. We hypothesize that certain patient characteristics associate with aspirin resistance. In addition, we will compare the effects of enteric-coated aspirin and chewable aspirin.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vanderbilt University; Vanderbilt University Medical Center
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• On aspirin 81-325mg daily at time of enrollment

• Documented stable coronary artery disease or > 6 months after coronary artery bypass grafting or interventional cardiac procedure

• Written informed consent

Exclusion Criteria:

• Pre-menopausal female

• Renal disease (creatinine >= 2 mg/dl)

• Anemia (Hematocrit < 30%)

• Thrombocytopenia (platelet count < 135,000/ul)

• Use of NSAIDs or coxibs within the previous 2 weeks

• Concurrent use of other anti-platelet agents

• Uncontrolled hypertension (systolic BP > 180 mmHg)

• Decompensated congestive heart failure

• Recent coronary syndrome (< 6 months)

• History of significant GI bleeding